Tuberous sclerosis complex (TSC) is a genetic disorder characterized by the development of a variety of benign tumors along with an increased risk of malignancy. Mechanism of disease is related to the mTOR pathway.
1In spite of this, individual features have different natural histories, and it is difficult to predict the extent to which a child with newly diagnosed disease is affected.
- Jozwiak J.
- Jozwiak S.
- Wlodarski P.
Possible mechanisms of disease development in tuberous sclerosis.
Lancet. 2008 Jan; 9: 73-79
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Pediatric Neurology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Possible mechanisms of disease development in tuberous sclerosis.Lancet. 2008 Jan; 9: 73-79
- Everolimus: in patients with subependymal giant cell astrocytoma associated with tuberous sclerosis complex.Pediatr Drugs. 2012; 14: 51-60
- Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial.Lancet. 2013; 9: 817-824
- Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.Cancer Treat Rev. 2013; 39: 784-792
Published online: May 29, 2014
© 2014 Elsevier Inc. Published by Elsevier Inc. All rights reserved.